抑二肽素A
| 中文名稱 | 抑二肽素A |
|---|---|
| 中文同義詞 | 抑二肽素A ≥97%(-20℃) (HPLC);L-異亮氨酰-L-脯氨酰-L-異亮氨酸;三肽抑制劑IPI;脯氨抑素;抑二肽素A;(2S,3S)-2-((S)-1-((2S,3S)-2-氨基-3-甲基戊酰基)吡咯烷-2-甲酰胺基)-3-甲基戊酸;DIPROTIN A,DIPEPTIDYL PEPTIDASE IV抑制劑;抑二肽素A,10 MM DMSO 溶液 |
| 英文名稱 | DIPROTIN A |
| 英文同義詞 | n-(1-l-isoleucyl-l-prolyl)-l-isoleucin;n-(1-l-isoleucyl-l-prolyl)-l-isoleucine;DIPROTIN A H2O;DIPEPTIDYLPEPTIDASE IV INHIBITOR I;ILE-PRO-ILE H2O;H-ILE-PRO-ILE-OH H2O;L-Isoleucyl-L-prolyl-L-isoleucine;Ile-Pro-Ile-OH |
| CAS號 | 90614-48-5 |
| 分子式 | C17H31N3O4 |
| 分子量 | 341.45 |
| EINECS號 | |
| 相關類別 | 原料藥;酶底物;Chiral Reagents;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Pepetides;peptides |
| Mol文件 | 90614-48-5.mol |
| 結(jié)構(gòu)式 |  |
抑二肽素A 性質(zhì)
| 沸點 | 583.1±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.140±0.06 g/cm3(Predicted) |
| 儲存條件 | -20°C |
| 溶解度 | DMSO:250.0(最大濃度 mg/mL);732.17(最大濃度 mM) 水:67.08(最大濃度 mg/mL);196.44(最大濃度 mM) |
| 酸度系數(shù)(pKa) | 3.72±0.22(Predicted) |
| 形態(tài) | 白色至類白色固體。 |
| 顏色 | 白色至米白色 |
| 水溶解性 | Soluble in water at 1mg/ml |
| InChI | 1S/C17H31N3O4/c1-5-10(3)13(18)16(22)20-9-7-8-12(20)15(21)19-14(17(23)24)11(4)6-2/h10-14H,5-9,18H2,1-4H3,(H,19,21)(H,23,24) |
| InChIKey | JNTMAZFVYNDPLB-UHFFFAOYSA-N |
| SMILES | CCC(C)C(N)C(=O)N1CCCC1C(=O)NC(C(C)CC)C(O)=O |
| CAS 數(shù)據(jù)庫 | 90614-48-5(CAS DataBase Reference) |
Diprotin A (Ile-Pro-Ile) 是二肽基肽酶 IV (DPP-IV) 的抑制劑。
IC50: DPP-IV
Diprotin A (100?μM; 30?minutes after CXCR4-blocker or Src-inhibitor treatment) induces the phosphorylation of Src [Tyr 416] and VE-cadherin [Tyr731] in hECs in both normoxia and H/R conditions in human endothelial cells and disrupts endothelial cell-to-cell junctions, which are attenuated by CXCR4 (receptor of SDF-1α)-blocker or Src-inhibitor.
Western Blot Analysis
| Cell Line: | Human endothelial cells [1] |
| Concentration: | 100?μM |
| Incubation Time: | 30?minutes after CXCR4-blocker or Src-inhibitor treatment |
| Result: | Induced the phosphorylation of Src [Tyr 416] and VE-cadherin [Tyr731] in hECs. |
Diprotin A (intraperitoneal injection; 70?μg/kg; twice daily; 7 days) increases the phosphorylation of Src and VE-cadherin and aggravates vascular leakage in the retinas. Collectively, Diprotin A induces vascular leakage by augmenting the SDF-1α/CXCR4/Src/VE-cadherin signaling pathway.
| Animal Model: | Streptozotocin-induced diabetic retinopathy model in wild-type C57/BL6 mice |
| Dosage: | 70?μg/kg |
| Administration: | Intraperitoneal injection; twice daily; 7 days |
| Result: | Induced vascular leakage by augmenting the SDF-1α/CXCR4/Src/VE-cadherin signaling pathway. |
安全信息
| WGK Germany | 3 |
|---|---|
| RTECS號 | NR4737000 |
| 存儲類別 | 11 - 可燃固體 |
| 提供商 | 語言 |
|---|---|
|
英文
|
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-111174R | 抑二肽素A Diprotin A (Standard) | 90614-48-5 | 5 mg | 1500元 |
| 2026/06/05 | HY-111174R | 抑二肽素A Diprotin A (Standard) | 90614-48-5 | 10 mg | 2250元 |